Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
A 46 year old woman with a history of dilated cardiomyopathy, an ejection fraction of 10% and a left ventricular thrombus, HIV, hypertension, and a history of hepatitis B, was admitted with increasing shortness of breath, paroxysmal nocturnal dyspnoea (PND), orthopnoea, and pedal oedema over a three week period. On admission, the patient was in respiratory distress and hypertensive. Her cardiovascular examination showed tachycardia and an S3, and her respiratory examination revealed crackles throughout; she also had pedal oedema. The patient was admitted and treated for pulmonary oedema with aggressive diuresis. On the second day after admission the patient had a cardiac arrest and was resuscitated, requiring endotracheal intubation. Subsequent to this episode the patient became hypotensive; she also had fevers and a chest x ray showed a left lower lobe infiltrate. She was treated for sepsis and started on fluids and noradrenaline (norepinephrine). A two dimensional echocardiogram showed a dilated left and right ventricle with an ejection fraction of 10%, and two thrombi—one measuring 4.1 × 3.2 cm and the other 1.2 × 1.6 cm (panel). Both thrombi were freely mobile, with the large one almost obliterating the left ventricular cavity; there was also a hint of a right ventricular thrombus. The patient was started on dobutamine and weaned off noradrenaline. Her blood pressure stabilised over the next few days and her fluid boluses were stopped; she was also placed on anticoagulation with enoxaparin. However, on day 5 after admission, the patient had an embolic stroke in the right gangliocapsular region. A repeat echocardiogram no longer revealed any thrombus. The patient was eventually discharged with minimal signs of the stroke. She was clinically stable at six months follow up.